John L Sullivan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10869324/publications.pdf

Version: 2024-02-01

		28274	22166
114	19,122	55	113
papers	citations	h-index	g-index
117	117	117	20809
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ten Years of Newborn Screening for Severe Combined Immunodeficiency (SCID) in Massachusetts. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2060-2067.e2.	3.8	20
2	Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. PLoS ONE, 2016, 11, e0154391.	2.5	31
3	Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. JAMA - Journal of the American Medical Association, 2014, 312, 729.	7.4	586
4	Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset. Blood, 2013, 121, 2669-2677.	1.4	208
5	Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates. Human Vaccines and Immunotherapeutics, 2012, 8, 1638-1647.	3.3	2
6	Genotypic and functional properties of early infant HIV-1 envelopes. Retrovirology, 2011, 8, 67.	2.0	36
7	Broad Cross-Reactive TCR Repertoires Recognizing Dissimilar Epstein-Barr and Influenza A Virus Epitopes. Journal of Immunology, 2010, 185, 6753-6764.	0.8	57
8	Infectious Mononucleosis. New England Journal of Medicine, 2010, 362, 1993-2000.	27.0	474
9	Low-Cost HIV-1 Diagnosis and Quantification in Dried Blood Spots by Real Time PCR. PLoS ONE, 2009, 4, e5819.	2.5	40
10	On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood, 2008, 111, 1420-1427.	1.4	118
11	Immunopathogenesis of HIV-1 Infection. , 2008, , 652-653.		O
12	Influence of EBV on the Peripheral Blood Memory B Cell Compartment. Journal of Immunology, 2007, 179, 3153-3160.	0.8	45
13	Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infectious Diseases, 2007, 7, 60.	2.9	20
14	Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet, The, 2006, 368, 511-521.	13.7	33
15	Inappropriate Model-Fitting Methods May Lead to Significant Underestimates of Viral Decay Rates in HIV Dynamic Studies. Journal of Acquired Immune Deficiency Syndromes, 2006, 21, 426.	0.3	2
16	Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters. Journal of Infectious Diseases, 2006, 193, 685-692.	4.0	95
17	Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18093-18098.	7.1	100
18	Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice. Journal of Infectious Diseases, 2005, 191, 507-514.	4.0	146

#	Article	IF	CITATIONS
19	Pneumonitis and Multi-Organ System Disease in Common Marmosets (Callithrix jacchus) Infected with the Severe Acute Respiratory Syndrome-Associated Coronavirus. American Journal of Pathology, 2005, 167, 455-463.	3.8	101
20	Nuclear Localization of HIV Type 1 Vif Isolated from a Long-Term Asymptomatic Individual and Potential Role in Virus Attenuation. AIDS Research and Human Retroviruses, 2005, 21, 565-574.	1.1	22
21	Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. Journal of Clinical Investigation, 2005, 115, 3602-3612.	8.2	145
22	A Trial of Three Antiretroviral Regimens in HIV-1–Infected Children. New England Journal of Medicine, 2004, 350, 2471-2480.	27.0	145
23	Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 239-244.	7.1	250
24	Efficient Replication of Severe Acute Respiratory Syndrome Coronavirus in Mouse Cells Is Limited by Murine Angiotensin-Converting Enzyme 2. Journal of Virology, 2004, 78, 11429-11433.	3.4	164
25	Acute Infection with Epstein-Barr Virus Targets and Overwhelms the Peripheral Memory B-Cell Compartment with Resting, Latently Infected Cells. Journal of Virology, 2004, 78, 5194-5204.	3.4	150
26	The Impact of Race/Ethnicity on Mother-to-Child HIV Transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 800-807.	2.1	14
27	Alterations in HIV-1 LTR promoter activity during AIDS progression. Virology, 2003, 317, 109-118.	2.4	18
28	Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426, 450-454.	27.8	5,168
29	A Multicenter Randomized Controlled Trial of Nevirapine Versus a Combination of Zidovudine and Lamivudine to Reduce Intrapartum and Early Postpartum Motherâ€toâ€Child Transmission of Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 2003, 187, 725-735.	4.0	328
30	Multicenter Evaluation of Use of Dried Blood and Plasma Spot Specimens in Quantitative Assays for Human Immunodeficiency Virus RNA: Measurement, Precision, and RNA Stability. Journal of Clinical Microbiology, 2003, 41, 1888-1893.	3.9	150
31	Differential Kinetics and Specificity of EBV-Specific CD4+and CD8+T Cells During Primary Infection. Journal of Immunology, 2003, 170, 2590-2598.	0.8	86
32	Predose Infant Nevirapine Concentration With the Two-Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine Dose. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 153-156.	2.1	56
33	Prevention of Mother-to-Child Transmission of HIV-What Next?. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, S67-S72.	2.1	18
34	Enhanced Culture Method for Detection of Replication-Competent Virus in Peripheral Blood Mononuclear Cells of HIV Type 1-Infected Individuals. AIDS Research and Human Retroviruses, 2002, 18, 577-583.	1.1	2
35	Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9503-9508.	7.1	96
36	Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316. Journal of Infectious Diseases, 2002, 186, 181-188.	4.0	117

#	Article	IF	CITATIONS
37	Phenotypic and Functional Heterogeneity of EBV Epitope-Specific CD8+T Cells. Journal of Immunology, 2002, 168, 4184-4191.	0.8	78
38	Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission (SUBTITLE) A Randomized Trial (SUBTITLE). JAMA - Journal of the American Medical Association, 2002, 288, 189.	7.4	317
39	Pediatric HIV-1 infection: advances and remaining challenges. AIDS Reviews, 2002, 4, 21-6.	1.0	31
40	Sustainability metrics for vehicles. Pure and Applied Chemistry, 2001, 73, 1273-1276.	1.9	3
41	Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 2001, 70, 24-32.	4.7	8
42	Infrequent Detection of HIV-1-Specific, But Not Cytomegalovirus-Specific, CD8+ T Cell Responses in Young HIV-1-Infected Infants. Journal of Immunology, 2001, 167, 7134-7140.	0.8	78
43	Abnormal T Cell Receptor Signal Transduction of CD4 Th Cells in X-Linked Lymphoproliferative Syndrome. Journal of Immunology, 2001, 167, 2657-2665.	0.8	38
44	CD4 Down-Modulation by Human Immunodeficiency Virus Type 1 Nef Correlates with the Efficiency of Viral Replication and with CD4 + T-Cell Depletion in Human Lymphoid Tissue Ex Vivo. Journal of Virology, 2001, 75, 10113-10117.	3.4	89
45	Modulation of Different Human Immunodeficiency Virus Type 1 Nef Functions during Progression to AIDS. Journal of Virology, 2001, 75, 3657-3665.	3.4	143
46	Differential Evolution and Stability of Epitope-Specific CD8+ T Cell Responses in EBV Infection. Journal of Immunology, 2001, 167, 4450-4457.	0.8	97
47	The Changing Face of Pediatric HIV-1 Infection. New England Journal of Medicine, 2001, 345, 1568-1569.	27.0	22
48	Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatric Infectious Disease Journal, 2001, 20, 746-751.	2.0	33
49	NEVIRAPINE PHARMACOKINETICS IN PREGNANT WOMEN AND IN THEIR INFANTS AFTER IN UTERO EXPOSURE. Pediatric Infectious Disease Journal, 2001, 20, 803-805.	2.0	64
50	Prevention and Treatment of Pediatric HIV Infection (Contempo 1998: Updates Linking Evidence and) Tj ETQq0 (0 o rgBT /C 0.1	Overlock 10 Tf O
51	Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nature Medicine, 2000, 6, 76-81.	30.7	401
52	Unusual Polymorphisms in Human Immunodeficiency Virus Type 1 Associated with Nonprogressive Infection. Journal of Virology, 2000, 74, 4361-4376.	3.4	152
53	Attenuation of Human Immunodeficiency Virus Type 1 Cytopathic Effects by Replacing a 424-bp Region of Envelope from a Noncytopathic Biological Clone. AIDS Research and Human Retroviruses, 2000, 16, 125-137.	1.1	2
54	Early Therapy of Vertical Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Control of Viral Replication and Absence of Persistent HIV-1-Specific Immune Responses. Journal of Virology, 2000, 74, 6984-6991.	3.4	191

#	Article	IF	Citations
55	Regulation of Human Cell Engraftment and Development of EBV-Related Lymphoproliferative Disorders in Hu-PBL- <i>scid</i> Mice. Journal of Immunology, 2000, 165, 518-527.	0.8	55
56	Resistance to Apoptosis in HIV-Infected CD4+ T Lymphocytes Is Mediated by Macrophages: Role for Nef and Immune Activation in Viral Persistence. Journal of Immunology, 2000, 165, 6437-6446.	0.8	61
57	VIRAL AND IMMUNOPATHOGENESIS OF VERTICAL HIV-1 INFECTION. Pediatric Clinics of North America, 2000, 47, 65-78.	1.8	10
58	Inappropriate Model-Fitting Methods May Lead to Significant Underestimates of Viral Decay Rates in HIV Dynamic Studies. Journal of Acquired Immune Deficiency Syndromes, 1999, 21, 426.	0.3	3
59	Declining CD4 T-Cell Counts in a Person Infected withnef-Deleted HIV-1. New England Journal of Medicine, 1999, 340, 236-237.	27.0	114
60	Longâ€Term Nonprogressive Infection with Human Immunodeficiency Virus Type 1 in a Hemophilia Cohort. Journal of Infectious Diseases, 1999, 180, 1790-1802.	4.0	51
61	The abnormal gene in X-linked lymphoproliferative syndrome. Current Opinion in Immunology, 1999, 11, 431-434.	5.5	27
62	Inappropriate Model-Fitting Methods May Lead to Significant Underestimates of Viral Decay Rates in HIV Dynamic Studies. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 426.	2.1	8
63	Dynamics of Human Immunodeficiency Virus Type 1 Replication in Vertically Infected Infants. Journal of Virology, 1999, 73, 362-367.	3.4	78
64	Sequence Variations in Human Immunodeficiency Virus Type 1 Nef Are Associated with Different Stages of Disease. Journal of Virology, 1999, 73, 5497-5508.	3.4	100
65	Changes in thymic function with age and during the treatment of HIV infection. Nature, 1998, 396, 690-695.	27.8	1,778
66	Combination Treatment with Zidovudine, Didanosine, and Nevirapine in Infants with Human Immunodeficiency Virus Type 1 Infection. New England Journal of Medicine, 1997, 336, 1343-1349.	27.0	215
67	Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children. New England Journal of Medicine, 1997, 336, 1704-1712.	27.0	148
68	Early HIV-1 Envelope-specific Cytotoxic T Lymphocyte Responses in Vertically Infected Infants. Journal of Experimental Medicine, 1997, 185, 1153-1162.	8.5	61
69	Human Immunodeficiency Virus Type 1â€Specific Cytotoxic T Lymphocytes (CTL), Virus Load, and CD4 T Cell Loss: Evidence Supporting a Protective Role for CTL In Vivo. Journal of Infectious Diseases, 1997, 176, 118-125.	4.0	109
70	In Vitro Characterization of Adult Primary Human Immunodeficiency Virus Type 1: Demonstration of Distinctive Single ell Killing Phenotypes in Spite of Similar Levels of Viral Replication. Journal of Infectious Diseases, 1997, 176, 933-940.	4.0	7
71	Activity of Human Immunodeficiency Virus Type 1 Promoter/TAR Regions andtat1 Genes Derived from Individuals with Different Rates of Disease Progression. Virology, 1997, 232, 319-331.	2.4	35
72	Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. Journal of Pediatrics, 1996, 129, 410-418.	1.8	15

#	Article	IF	CITATIONS
73	<i>In Vitro</i> Characterization of HIV Type 1 Biological Clones from Asymptomatic and Symptomatic Pediatric Patients. AIDS Research and Human Retroviruses, 1996, 12, 1585-1593.	1.1	8
74	Community-wide HIV counselling and testing in central Massachusetts: Who is retested and does their behavior change?. Journal of Community Health, 1996, 21, 11-22.	3.8	28
75	Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. New England Journal of Medicine, 1996, 335, 1621-1629.	27.0	802
76	High Levels of Human Peripheral Blood Mononuclear Cell Engraftment and Enhanced Susceptibility to Human Immunodeficiency Virus Type 1 Infection in NOD/LtSz-scid/scid Mice. Journal of Infectious Diseases, 1995, 172, 974-982.	4.0	159
77	Absence of Intact nef Sequences in a Long-Term Survivor with Nonprogressive HIV-1 Infection. New England Journal of Medicine, 1995, 332, 228-232.	27.0	1,015
78	Quantitative Assessment of Human Immunodeficiency Virus Type 1 Replication in Human Xenografts of Acutely Infected Hu-PBL-SCID Mice. AIDS Research and Human Retroviruses, 1994, 10, 279-284.	1.1	24
79	Detection of Cell-Free Epstein-Barr Virus DNA in Serum during Acute Infectious Mononucleosis. Journal of Infectious Diseases, 1994, 170, 436-439.	4.0	93
80	Non-Syncytium-Inducing HIV Type 1 Isolated from Infected Individuals Replicates in MT-2 Cells. AIDS Research and Human Retroviruses, 1994, 10, 1613-1618.	1.1	8
81	Pathogenesis of Vertical HIV-1 Infection: Implications for Intervention and Management. Pediatric Annals, 1994, 23, 159-166.	0.8	5
82	Reactive Histiocytic Disorders. American Journal of Clinical Pathology, 1993, 99, 459-463.	0.7	37
83	Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. Aids, 1993, 7, 1181-1184.	2.2	27
84	Diagnosis of Vertical Human Immunodeficiency Virus Type 1 Infection by Whole Blood Culture. Journal of Infectious Diseases, 1992, 166, 1146-1148.	4.0	20
85	Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. Journal of Pediatrics, 1991, 119, 230-236.	1.8	105
86	Inhibition of Human Immunodeficiency Virus Type I (HIV-I) Replication by the Dipyridodiazepinone BI-RG-587. Journal of Infectious Diseases, 1991, 163, 966-970.	4.0	120
87	RACIAL/ETHNIC DIFFERENCES IN HTV-1 SEROPREVALENCE AND RISKY BEHAVIORS AMONG INTRAVENOUS DRUG USERS IN A MULTISITE STUDY. American Journal of Epidemiology, 1990, 132, 837-846.	3.4	67
88	Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science, 1990, 250, 1411-1413.	12.6	772
89	X chromosome inactivation patterns in obligate carriers of X-linked lymphoproliferative syndrome. Clinical Immunology and Immunopathology, 1990, 55, 486-491.	2.0	13
90	Mapping the mutation causing the X-linked lymphoproliferative syndrome in relation to restriction fragment length polymorphisms on Xq. Human Genetics, 1989, 82, 349-53.	3.8	28

#	Article	IF	Citations
91	Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. Human Genetics, 1989, 82, 354-8.	3.8	48
92	Severe Herpesvirus Infections in an Adolescent without Natural Killer Cells. New England Journal of Medicine, 1989, 320, 1731-1735.	27.0	1,172
93	EPSTEIN-BARR-VIRUS-RELATED MALIGNANT B CELL LYMPHOPLASMACYTIC LYMPHOMA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION FOR APLASTIC ANEMIA. Transplantation, 1987, 44, 244-248.	1.0	22
94	Isolation of human immunodeficiency virus from hemophiliacs: Correlation with clinical symptoms and immunologic abnormalities. Journal of Pediatrics, 1987, 111, 672-677.	1.8	26
95	Hematologic Consequences of Epstein-Barr Virus Infection. Hematology/Oncology Clinics of North America, 1987, 1, 397-417.	2.2	9
96	The "chronic, active epstein-barr virus infection―syndrome and primary fibromyalgia. Arthritis and Rheumatism, 1987, 30, 1132-1136.	6.7	130
97	Hemophiliac immunodeficiency: Influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses. Journal of Pediatrics, 1986, 108, 504-510.	1.8	63
98	Serological Characterization of HTLV-III Infection in AIDS and Related Disorders. Journal of Infectious Diseases, 1986, 153, 736-742.	4.0	66
99	Lymphoma of host origin in a marrow transplant recipient in remission of acute myeloid leukemia and receiving cyclosporin A. American Journal of Hematology, 1985, 18, 73-83.	4.1	21
100	Epstein-Barr Virus and the X- Linked Lymphoproliferative Syndrome. , 1985, , 229-250.		5
101	Epstein–Barr-Virus Induced Lymphoproliferation. New England Journal of Medicine, 1984, 311, 1163-1167.	27.0	94
102	Virologic Studies in a Case of Transfusion-Associated AIDS. New England Journal of Medicine, 1984, 311, 1419-1422.	27.0	60
103	Treatment of life-threatening Epstein-Barr virus infections with acyclovir. American Journal of Medicine, 1982, 73, 262-266.	1.5	59
104	Treatment of the ?on-off? phenomenon in parkisnonism with lithium carbonate. Annals of Neurology, 1982, 12, 375-379.	5. 3	27
105	In vitro responses to a B-lymphoblastoid cell line in immunodeficiency diseases. Journal of Clinical Immunology, 1982, 2, 150-155.	3.8	2
106	Differences in synthesis of membrane proteins by leukemic cells from spleen and peripheral blood indicate distinct subsets of malignant cells in a patient with prolymphocytic leukemia. American Journal of Hematology, 1981, 11, 261-270.	4.1	9
107	Antibodies to epstein-barr virus-specific antigens in patients with hairy-cell leukemia. International Journal of Cancer, 1981, 27, 453-458.	5.1	34
108	Subsets of hairy cell leukemia defined by unique membrane proteins. Leukemia Research, 1980, 4, 477-488.	0.8	20

#	Article	IF	CITATIONS
109	Formycin B, Purine Nucleoside Phosphorylase and Lymphocyte Function. Immunological Investigations, 1980, 9, 257-267.	0.8	13
110	X-Linked Lymphoproliferative Syndrome Registry report. Journal of Pediatrics, 1980, 96, 669-673.	1.8	89
111	Epstein-barr virus infection following bone-marrow transplantation. International Journal of Cancer, 1978, 22, 132-135.	5.1	18
112	Serum dopamine-β-hydroxylase in chronic alcoholism. Psychological Medicine, 1978, 8, 505-508.	4.5	1
113	Cell-Mediated Immunity to Epstein–Barr-Virus-Transformed Lymphoblastoid Cells in Acute Infectious Mononucleosis. New England Journal of Medicine, 1975, 293, 1159-1163.	27.0	132
114	Cell-Mediated Immunity in Acute Infectious Mononucleosis 1. Proceedings of the International Symposium on Comparative Leukemia Research, 1975, 43, 278-280.	0.1	1